Standout Papers

Inotuzumab Ozogamicin versus Standard The... 2003 2026 2010 2018 844
  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia (2016)
    Hagop M. Kantarjian, Daniel J. DeAngelo et al. New England Journal of Medicine
  2. Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin (2003)
    Shahrokh Falati, Peter L. Gross et al. The Journal of Experimental Medicine

Immediate Impact

6 by Nobel laureates 20 from Science/Nature 74 standout
Sub-graph 1 of 18

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
1 intermediate paper

Works of Erik Vandendries being referenced

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
2020
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Erik Vandendries 1281 1686 1396 85 3.4k
Carlos Graux 1344 941 2107 89 3.4k
Renato Bassan 2072 1144 2359 162 4.0k
Marı́a Dolores Caballero 451 1173 1108 73 2.7k
Ellin Berman 868 1200 2186 99 3.7k
R Ohno 1254 1144 4067 102 5.7k
Stefan Hohaus 329 1330 1499 164 4.1k
J. S. Malpas 812 1906 1733 109 5.4k
Anna Guarini 604 524 1109 92 2.5k
Tibor Kovacsovics 1055 859 2269 123 3.6k
David Zahrieh 382 1738 1056 72 4.3k

All Works

Loading papers...

Rankless by CCL
2026